FDA's First-Ever Vote on a Multi-Cancer Blood Test: What Labs Need to Know
Short answer: On September 23, 2026, an FDA advisory panel will cast the first-ever vote on a premarket approval (PMA) application for a multi-cancer early detection (MCED) test — GRAIL's Galleri. The vote is non-binding, but FDA staff already flagged high specificity alongside a real gap in stage I sensitivity and an unmet "early detection" endpoint in the NHS-Galleri trial. Labs and ordering clinicians should read the underlying data now, not wait for the headline.
What's Happening on September 23
The FDA's Molecular and Clinical Genetics Panel of the Medical Devices Advisory Committee convenes on September 23, 2026, from 9:00 a.m. to 6:00 p.m. ET to review and vote on GRAIL Inc.'s premarket approval application for the Galleri test, a next-generation sequencing (NGS)-based in vitro diagnostic that detects cancer-specific methylation patterns in cell-free DNA from a standard blood draw (FDA.gov). GRAIL submitted the PMA application on January 29, 2026, and the meeting marks the first time an FDA advisory committee has reviewed a PMA for an MCED test — a screening category that until now has existed almost entirely as laboratory-developed tests (LDTs) outside FDA's premarket review (Targeted Oncology).
The application draws on two large studies: PATHFINDER 2, which followed 25,490 participants for one year, and NHS-Galleri, a randomized controlled trial with more than 70,000 participants in its intervention arm. GRAIL received breakthrough device designation for Galleri back in 2018, and the public comment docket (FDA-2026-N-8004) closed September 16. The panel's recommendation does not bind the agency's final decision, but FDA typically follows advisory committee votes closely, and a positive vote would be a meaningful signal for the entire MCED category — not just for GRAIL.
The Performance Data FDA Reviewers Are Weighing
FDA's staff briefing document, released ahead of the meeting, found that Galleri met its prespecified success criteria for specificity, episode sensitivity, and cancer signal origin prediction accuracy, with a "very low false-positive rate" and no device-related adverse events (source reporting on the briefing via FDA staff review coverage). The specific numbers matter for anyone advising patients or building coverage policy around this category:
In plain terms: fewer than 3 in 1,000 cancer-free people got a false-positive signal in either trial, which is the headline number GRAIL and FDA staff both point to. But Galleri detected roughly one in three cancers diagnosed within 12 months of testing — 35.0% in PATHFINDER 2 and 31.6% in NHS-Galleri's first screening round. When the test was positive, it correctly identified cancer 77.0% of the time in PATHFINDER 2 versus 66.2% in NHS-Galleri, meaning close to a third of positive results in the UK trial turned out to be false alarms.
The "Early Detection" Question That Could Decide the Vote
FDA reviewers flagged one substantive open question: whether the evidence supports calling Galleri an "early detection" test at all. NHS-Galleri, the randomized controlled arm of the evidence package, missed its primary endpoint — it did not show a statistically significant reduction in late-stage cancer diagnoses (FDA staff briefing coverage). Staging data explains why that matters to reviewers:
Galleri caught only about one in five stage I cancers (21.4% in PATHFINDER 2, 13.6% in NHS-Galleri) versus roughly 60% of stage IV disease — the opposite of what an "early detection" test is meant to do well. Among false positives, about half of patients underwent an invasive diagnostic procedure before resolution, with a median time to resolution of 75 days. None of this necessarily sinks the application: FDA staff had no outstanding questions on analytical performance, study design, or the primary safety analysis. But the panel's discussion of whether "early detection" is the right label — and what that means for how ordering clinicians should counsel patients — is worth watching closely regardless of how the vote lands.
Why This Vote Reaches Beyond One Company
The timing is not incidental. On February 3, 2026, the Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act became law as part of H.R. 7148. It authorizes CMS to cover blood-based MCED tests "once approved by the FDA and shown to have clinical benefit" — but coverage cannot begin until a test actually clears FDA review. No MCED test currently holds FDA approval; every MCED product on the market today, including Galleri, is offered as a laboratory-developed test outside FDA's premarket pathway.
Under the law, coverage would phase in starting at age 68 in the first eligible year, expanding by one additional age year annually, with testing limited to once every 11 months. That structure only activates once a qualifying MCED test has FDA clearance and demonstrated clinical benefit — which is exactly what Wednesday's panel is being asked to weigh in on. A positive vote and eventual approval would not, by itself, guarantee CMS coverage or a specific price, but it would remove the single biggest structural blocker between the 2026 law and an actual Medicare benefit (Congress.gov).
What Labs and Ordering Clinicians Should Do Now
Whichever way the vote goes, a few things are true for molecular labs, medical directors, and RCM teams tracking this space today. First, the LDT-versus-PMA distinction is about to become commercially meaningful in a way it hasn't been for MCED tests before — labs offering their own multi-cancer screening panels should understand where their assay sits relative to a potential FDA-cleared standard, and how that affects payer conversations. Second, prior-authorization and medical-necessity documentation for any MCED-adjacent test should already account for the sensitivity and false-positive tradeoffs FDA staff highlighted; that data is now public and payers will use it. Third, coding and RCM teams should watch for PLA/CPT movement tied to Galleri or any approved MCED test, since a distinct code is typically a prerequisite for consistent claims adjudication. Finally, genetic counselors and ordering clinicians should be ready to walk patients through what a positive Galleri-type result actually means: strong specificity, meaningfully incomplete early-stage sensitivity, and a real chance of an invasive workup for a result that turns out to be a false positive.
For background on how CMS currently evaluates genetic and molecular tests for coverage — the NCD, LCD, and MolDX framework this MCED pathway will eventually intersect with — see our Medicare coverage guide for genetic testing. And if your lab is navigating payer pushback on newer test categories, our breakdown of why genetic testing claims get denied covers the documentation patterns that hold up under review. ScreenMyGene tracks coverage and regulatory developments like this one as they unfold, so ordering teams aren't caught off guard by a policy shift.
Frequently Asked Questions
What is the Galleri test?
Galleri, made by GRAIL, is a prescription-only blood test that uses next-generation sequencing to detect cancer-specific methylation patterns in cell-free DNA. It is intended for adults 50 and older as a screening tool that supplements, not replaces, guideline-recommended cancer screenings, and it predicts a likely cancer origin to guide follow-up diagnostic workup.
Why does the September 23 FDA panel vote matter?
It is the first time an FDA advisory committee has reviewed a premarket approval application for a multi-cancer early detection test. The vote is non-binding, but FDA's eventual decision will set a regulatory precedent for how the entire MCED category — currently sold only as laboratory-developed tests — is evaluated going forward.
Does a positive panel vote mean Medicare will start covering MCED tests?
Not automatically. The Nancy Gardner Sewell Medicare MCED Screening Coverage Act, signed into law February 3, 2026, authorizes CMS to cover FDA-approved MCED tests with demonstrated clinical benefit, with coverage phased in starting at age 68 as early as 2028. FDA approval is a prerequisite, not a guarantee of coverage timing or payment rate.
What is the "early detection" concern FDA staff raised?
NHS-Galleri, the randomized controlled trial in GRAIL's evidence package, did not meet its primary endpoint of significantly reducing late-stage cancer diagnoses. Combined with stage I detection rates of 13.6%–21.4% versus roughly 60% for stage IV disease, FDA reviewers are asking whether "early detection" accurately describes the test's demonstrated performance.
Can labs legally offer multi-cancer screening tests today without FDA approval?
Yes, as laboratory-developed tests (LDTs) under the applicable regulatory framework, which is how Galleri and similar products have been offered to date. FDA approval would shift a test into the premarket-cleared category, which carries different regulatory and, potentially, coverage implications than the LDT pathway.
This article is intended for laboratory professionals, medical directors, genetic counselors, and revenue cycle teams as general regulatory and policy information. It is not clinical, legal, or coding advice for any specific patient, payer contract, or claim. Confirm current FDA status, CMS coverage policy, and payer-specific requirements directly with the relevant agency or payer before making coverage or billing decisions.
Sources: FDA.gov Advisory Committee Calendar; Federal Register notice FDA-2026-N-8004; GRAIL, Inc. press releases; Targeted Oncology; The Cancer Letter; Medical Daily's reporting on the FDA staff briefing document; Congress.gov (H.R. 842 / H.R. 7148, Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act); AZBio and American Cancer Society Cancer Action Network reporting on the Act's enactment.